---
// src/pages/science/genetics.astro
import BaseLayout from "../../layouts/BaseLayout.astro";
import { useTranslations } from "../../i18n";

const t = useTranslations('en');
---

<BaseLayout 
  title={t.sections.genetics.title}
  description="Genetic factors in post-vaccination narcolepsy: HLA associations, B3GALT4 variants, and GT1B regulation."
>
  <section class="bg-gradient-to-b from-slate-900 to-slate-800 text-white py-16">
    <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
      <nav class="text-sm text-slate-400 mb-4">
        <a href="/" class="hover:text-white transition-colors">Home</a>
        <span class="mx-2">/</span>
        <a href="/science/" class="hover:text-white transition-colors">Science</a>
        <span class="mx-2">/</span>
        <span class="text-white">Genetics</span>
      </nav>
      <h1 class="text-4xl md:text-5xl font-bold mb-4">{t.sections.genetics.title}</h1>
      <p class="text-xl text-slate-300 max-w-3xl">
        {t.sections.genetics.subtitle}
      </p>
    </div>
  </section>

  <section class="py-12">
    <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
      <div class="prose-science">
        
        <h2>HLA-DQB1*06:02 Association</h2>
        <p>
          Virtually all cases of Pandemrix-associated narcolepsy occur in individuals carrying 
          the HLA-DQB1*06:02 allele. This strong genetic association has been interpreted as 
          evidence for autoimmune etiology — HLA molecules present antigens to T cells, and 
          DQB1*06:02 may efficiently present H1N1-derived peptides that cross-react with 
          orexin receptor epitopes.
        </p>

        <div class="key-concept">
          <div class="key-concept-title">Block Inheritance — The Critical Point</div>
          <p class="mb-0">
            HLA genes are inherited in blocks (haplotypes). The DQB1*06:02 allele is in strong 
            linkage disequilibrium with many nearby genes. <strong>Critically, the ganglioside 
            synthesis gene B3GALT4 is located at 6p21.32 — directly within the HLA region.</strong> 
            The true susceptibility gene may not be DQB1*06:02 itself, but B3GALT4 or another linked variant.
          </p>
        </div>

        <h2>The B3GALT4 Connection — Key Discovery</h2>
        <p>
          <span class="gene-name">B3GALT4</span> (Beta-1,3-galactosyltransferase 4) is located on 
          <strong>Chromosome 6p21.32</strong> — the same chromosomal band as the HLA complex. 
          This gene encodes the enzyme that catalyzes a critical step in GT1b biosynthesis:
        </p>
        
        <div class="bg-slate-100 rounded-lg p-4 my-6 font-mono text-sm">
          GD2 → <span class="text-red-600 font-bold">GD1b</span> → GT1b
          <br/>
          <span class="text-slate-500">↑ B3GALT4 adds galactose here</span>
        </div>

        <p>
          This is potentially the most important genetic finding for this hypothesis:
        </p>
        <ul>
          <li>B3GALT4 is <strong>essential</strong> for GT1b production</li>
          <li>It lies in the <strong>same chromosomal region</strong> as HLA-DQB1</li>
          <li>Variants affecting B3GALT4 expression could directly alter GT1b levels in neurons</li>
          <li>The apparent "HLA association" may actually be a <strong>B3GALT4 association</strong></li>
        </ul>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">Reinterpreting the HLA Association</h4>
          <p class="text-amber-700 text-sm mb-0">
            If narcolepsy susceptibility is driven by B3GALT4 variants (affecting GT1b synthesis) 
            rather than HLA-DQB1*06:02 (affecting antigen presentation), this fundamentally changes 
            our understanding of the mechanism. The disease would be primarily a disorder of 
            <em>ganglioside-mediated transport</em> rather than <em>HLA-mediated autoimmunity</em> — 
            though autoimmunity remains the downstream effector.
          </p>
        </div>

        <h2>Chromosome 6p21.3 — The Narcolepsy Region</h2>
        <p>
          The 6p21.3 region contains both the HLA complex and critical ganglioside-regulatory genes. 
          <strong>A key insight:</strong> Three genes are inherited together in the same haplotype 
          (linkage disequilibrium block), creating a "synergistic trinity" that may explain susceptibility.
        </p>

        <!-- Chromosome 6 Map -->
        <figure class="my-8">
          <img 
            src="/images/chromosome6-gene-map.svg" 
            alt="Chromosome 6p21 gene map showing physical positions of NEU1 (31.86 Mb), HLA-DQB1 (32.66 Mb), and B3GALT4 (33.28 Mb)"
            class="w-full rounded-lg border border-slate-700 shadow-lg"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>Physical map of chromosome 6p21:</strong> NEU1 (sialidase) and B3GALT4 (GT1b synthase) 
            flank the HLA-DQB1 locus. All three are inherited together due to strong linkage disequilibrium.
          </figcaption>
        </figure>
        
        <table class="w-full text-sm">
          <thead>
            <tr class="border-b bg-slate-50">
              <th class="text-left py-2 px-2">Gene</th>
              <th class="text-left py-2 px-2">Location</th>
              <th class="text-left py-2 px-2">Function</th>
              <th class="text-left py-2 px-2">Role in Hypothesis</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b bg-cyan-50">
              <td class="py-2 px-2"><span class="gene-name">NEU1</span></td>
              <td class="py-2 px-2 font-bold text-cyan-700">6p21.33</td>
              <td class="py-2 px-2">Neuraminidase 1 (sialidase)</td>
              <td class="py-2 px-2"><strong>KEY</strong> — Regulates TLR activation, removes sialic acid</td>
            </tr>
            <tr class="border-b bg-purple-50">
              <td class="py-2 px-2"><span class="gene-name">HLA-DQB1</span></td>
              <td class="py-2 px-2 font-bold text-purple-700">6p21.32</td>
              <td class="py-2 px-2">MHC class II</td>
              <td class="py-2 px-2"><strong>ANCHOR</strong> — Antigen presentation</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2 px-2"><span class="gene-name">B3GALT4</span></td>
              <td class="py-2 px-2 font-bold text-amber-700">6p21.32</td>
              <td class="py-2 px-2">GM1/GD1b synthase</td>
              <td class="py-2 px-2"><strong>KEY</strong> — Creates GD1b, precursor to GT1b</td>
            </tr>
          </tbody>
        </table>

        <!-- NEW SECTION: NEU1 -->
        <h2>The NEU1 Discovery — Immune Brakes and "Super-Enzymes"</h2>
        
        <div class="key-concept">
          <div class="key-concept-title">NEU1: The Missing Link in Immune Hyperactivation</div>
          <p class="mb-0">
            <span class="gene-name">NEU1</span> (Neuraminidase 1) is a sialidase that removes terminal sialic acids 
            from receptors. It lies at <strong>6p21.33</strong> — within the same haplotype block as HLA-DQB1. 
            GWAS data shows NEU1 variants are associated with narcolepsy at p = 6E-14, comparable to HLA signals.
          </p>
        </div>

        <p>
          NEU1's role in immune regulation is critical: it controls the "sialic acid brake" on Toll-like receptors (TLRs).
        </p>

        <div class="bg-cyan-50 border border-cyan-200 rounded-lg p-6 my-6">
          <h4 class="font-bold text-cyan-800 mb-4">The Siglec Brake System</h4>
          
          <div class="grid md:grid-cols-2 gap-4">
            <div class="bg-white rounded p-4 border border-cyan-200">
              <h5 class="font-bold text-cyan-700 mb-2">Normal State (Brakes ON)</h5>
              <ul class="text-slate-700 text-sm space-y-1">
                <li>• TLR4 is covered with sialic acids</li>
                <li>• Siglec receptors bind these sialic acids</li>
                <li>• Siglecs recruit phosphatases → signal OFF</li>
                <li>• Immune response is <strong>controlled</strong></li>
              </ul>
            </div>
            <div class="bg-white rounded p-4 border border-cyan-200">
              <h5 class="font-bold text-red-700 mb-2">NEU1 "Super-Enzyme" (Brakes OFF)</h5>
              <ul class="text-slate-700 text-sm space-y-1">
                <li>• NEU1 aggressively removes sialic acids</li>
                <li>• Siglecs cannot engage (brake disconnected)</li>
                <li>• TLR4 signals continuously → cytokine storm</li>
                <li>• Immune response is <strong>uncontrolled</strong></li>
              </ul>
            </div>
          </div>
        </div>

        <h3>Two Alternative Hypotheses for NEU1 Dysfunction</h3>
        <p>
          Interestingly, the observed hypersialylation in NT1 patients (3-fold increase in trisialylated N-glycans) 
          could result from <em>either</em> direction of NEU1 dysfunction:
        </p>

        <table class="w-full text-sm my-6">
          <thead>
            <tr class="border-b bg-slate-50">
              <th class="text-left py-2 px-2">Hypothesis</th>
              <th class="text-left py-2 px-2">NEU1 Status</th>
              <th class="text-left py-2 px-2">Serum Effect</th>
              <th class="text-left py-2 px-2">Immune Effect</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b">
              <td class="py-2 px-2 font-medium">A: "Lazy Enzyme"</td>
              <td class="py-2 px-2 text-red-600">Reduced activity</td>
              <td class="py-2 px-2">High sialylation (can't remove)</td>
              <td class="py-2 px-2">Receptors stay "sticky"</td>
            </tr>
            <tr class="border-b bg-cyan-50">
              <td class="py-2 px-2 font-medium">B: "Surface Defect"</td>
              <td class="py-2 px-2 text-cyan-600">Normal in lysosome, absent on surface</td>
              <td class="py-2 px-2">High sialylation (surface unmodified)</td>
              <td class="py-2 px-2">TLR brakes never released properly</td>
            </tr>
          </tbody>
        </table>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">The Sialidosis Paradox</h4>
          <p class="text-amber-700 text-sm mb-0">
            Complete NEU1 loss causes <strong>Sialidosis</strong> (lysosomal storage disease with severe symptoms). 
            NT1 patients don't have Sialidosis, so the NEU1 variant must be <em>subtle</em> — affecting regulation 
            or membrane translocation rather than complete enzyme loss. This "sub-clinical" defect creates 
            susceptibility without overt disease.
          </p>
        </div>

        <!-- Dual-Hit Hypothesis Diagram -->
        <h2>The Dual-Hit Hypothesis: Synergistic Enzyme Variants</h2>
        <p>
          We propose that the risk haplotype carries <em>two</em> enzyme variants that synergize:
        </p>

        <figure class="my-8">
          <img 
            src="/images/dual-hit-hypothesis.svg" 
            alt="Dual-Hit Hypothesis: B3GALT4 gain-of-function creates more GT1b targets, NEU1 regulation defect removes immune brakes"
            class="w-full rounded-lg border border-slate-200 shadow-lg bg-white"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>The Dual-Hit Hypothesis:</strong> B3GALT4 overproduction creates more GT1b "fuel" for viral binding, 
            while NEU1 dysfunction removes the immune system's "brakes," leading to uncontrolled inflammation.
          </figcaption>
        </figure>

        <div class="bg-slate-800 text-white rounded-lg p-6 my-6">
          <h4 class="font-bold text-cyan-400 mb-4">The Synergistic Trinity</h4>
          <table class="w-full text-sm">
            <thead>
              <tr class="border-b border-slate-600">
                <th class="text-left py-2 text-slate-300">Gene</th>
                <th class="text-left py-2 text-slate-300">Variant Type</th>
                <th class="text-left py-2 text-slate-300">Function in Pathogenesis</th>
              </tr>
            </thead>
            <tbody>
              <tr class="border-b border-slate-700">
                <td class="py-2 text-purple-400 font-bold">HLA-DQB1*06:02</td>
                <td class="py-2 text-slate-300">Structural</td>
                <td class="py-2 text-slate-300">The Lock — Presents mimicry peptides to T cells</td>
              </tr>
              <tr class="border-b border-slate-700">
                <td class="py-2 text-cyan-400 font-bold">NEU1</td>
                <td class="py-2 text-slate-300">Regulatory (GoF)</td>
                <td class="py-2 text-slate-300">The Ignition — Removes immune brakes, enables cytokine storm</td>
              </tr>
              <tr>
                <td class="py-2 text-amber-400 font-bold">B3GALT4</td>
                <td class="py-2 text-slate-300">Regulatory (GoF)</td>
                <td class="py-2 text-slate-300">The Fuel — Overproduces GT1b, creates target-rich environment</td>
              </tr>
            </tbody>
          </table>
        </div>

        <!-- NEW: Detailed mechanism illustrations -->
        <h2>The Siglec Brake System: How NEU1 Controls Immunity</h2>
        <p>
          NEU1 regulates immune activation through a sophisticated "brake" system involving 
          <strong>Siglec receptors</strong>. Sialic acids on TLR4 bind Siglec-E, which recruits 
          phosphatases that actively suppress signaling. NEU1 removes these sialic acids, 
          releasing the brake.
        </p>

        <figure class="my-8">
          <img 
            src="/images/tlr4-siglec-brake-system.svg" 
            alt="TLR4-Siglec brake system showing how NEU1 removes sialic acids to release immune brakes"
            class="w-full rounded-lg border border-slate-200 shadow-lg bg-white"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>The Siglec Brake System:</strong> Normal state (left) has TLR4 covered with sialic acids 
            that engage Siglec-E, suppressing inflammation. NEU1 "super-enzyme" (right) removes these sialic acids, 
            causing permanent brake failure and hyperinflammation.
          </figcaption>
        </figure>

        <h2>GT1b Exosome Shedding: Why No Storage Disease?</h2>
        <p>
          A critical question: if B3GALT4 overproduces GT1b, why don't patients develop a storage disease 
          like Tay-Sachs? The answer lies in the <strong>distinction between storage and secretion</strong>.
        </p>

        <figure class="my-8">
          <img 
            src="/images/gt1b-exosome-shedding.svg" 
            alt="Comparison between lysosomal storage disease and GT1b exosome shedding"
            class="w-full rounded-lg border border-slate-200 shadow-lg bg-white"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>Storage vs Shedding:</strong> In storage diseases (left), enzyme deficiency causes 
            intracellular accumulation and cell death. In super-enzyme overproduction (right), excess GT1b 
            is SHED via exosomes, keeping the cell healthy but creating an extracellular inflammatory environment.
          </figcaption>
        </figure>

        <div class="key-concept">
          <div class="key-concept-title">GT1b Exosomes as Endogenous Adjuvants</div>
          <p class="mb-0">
            Research shows that extracellular GT1b directly activates <strong>TLR2</strong> and induces 
            PI3K/Akt signaling. These GT1b-rich exosomes function as <strong>DAMPs</strong> (Damage-Associated 
            Molecular Patterns), priming microglia and astrocytes for inflammation. This creates a 
            "pre-inflammatory" environment in the hypothalamus that amplifies the autoimmune response.
          </p>
        </div>

        <h2>The Complete Pathogenesis Cascade</h2>
        <p>
          Integrating all components, we can reconstruct the complete 8-step cascade from genetic 
          predisposition to orexin neuron destruction:
        </p>

        <figure class="my-8">
          <img 
            src="/images/narcolepsy-pathogenesis-cascade.svg" 
            alt="Complete 8-step pathogenesis cascade from genetic predisposition to narcolepsy"
            class="w-full rounded-lg border border-slate-700 shadow-lg"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>The Complete Pathogenesis Cascade:</strong> From inherited haplotype (Step 1) through 
            NEU1-driven hyperactivation (Step 3), B3GALT4-driven exosome shedding (Step 5), and finally 
            blood-brain barrier breach leading to orexin neuron destruction (Step 8).
          </figcaption>
        </figure>

        <h3>Clinical Implications of the Model</h3>
        <div class="grid md:grid-cols-3 gap-4 my-6">
          <div class="bg-blue-50 border border-blue-200 rounded-lg p-4">
            <h4 class="font-bold text-blue-800 mb-2">Biomarkers</h4>
            <ul class="text-blue-700 text-sm space-y-1">
              <li>• Plasma GT1b-exosome levels</li>
              <li>• Monocyte sialidase activity</li>
              <li>• Pre-symptomatic risk identification</li>
            </ul>
          </div>
          <div class="bg-green-50 border border-green-200 rounded-lg p-4">
            <h4 class="font-bold text-green-800 mb-2">Potential Therapy</h4>
            <ul class="text-green-700 text-sm space-y-1">
              <li>• NEU1 inhibitors (specific sialidase blockers)</li>
              <li>• GT1b-exosome absorption</li>
              <li>• TLR2/TLR4 antagonists</li>
            </ul>
          </div>
          <div class="bg-purple-50 border border-purple-200 rounded-lg p-4">
            <h4 class="font-bold text-purple-800 mb-2">Prevention</h4>
            <ul class="text-purple-700 text-sm space-y-1">
              <li>• Pre-vaccination genetic screening</li>
              <li>• Risk haplotype identification</li>
              <li>• Personalized vaccine protocols</li>
            </ul>
          </div>
        </div>

        <h2>Complete GT1b Biosynthesis Pathway — Genetic Map</h2>
        <p>
          The enzymes required to synthesize GT1b are distributed across multiple chromosomes:
        </p>
        <table class="w-full text-sm">
          <thead>
            <tr class="border-b">
              <th class="text-left py-2">Gene</th>
              <th class="text-left py-2">Chromosome</th>
              <th class="text-left py-2">Reaction</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">ST3GAL5</span></td>
              <td class="py-2">2p11.2</td>
              <td class="py-2">LacCer → GM3 (initiates pathway)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">ST8SIA1</span></td>
              <td class="py-2">12p12.1</td>
              <td class="py-2">GM3 → GD3 (creates b-series)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">B4GALNT1</span></td>
              <td class="py-2">12q13.3</td>
              <td class="py-2">GD3 → GD2</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2"><span class="gene-name">B3GALT4</span></td>
              <td class="py-2 font-bold text-red-700">6p21.32 ⚠️</td>
              <td class="py-2"><strong>GD2 → GD1b</strong> (in HLA region!)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">ST3GAL2</span></td>
              <td class="py-2">16q22.1</td>
              <td class="py-2">GD1b → GT1b (final step)</td>
            </tr>
          </tbody>
        </table>

        <h2>Proposed Mechanism — Revised</h2>
        <p>
          The B3GALT4 discovery suggests a refined mechanism:
        </p>
        <ol>
          <li>
            <strong>Genetic susceptibility:</strong> Individuals with HLA-DQB1*06:02 carry a 
            linked B3GALT4 variant that increases GD1b/GT1b production
          </li>
          <li>
            <strong>Elevated GT1b:</strong> Higher GT1b levels on nerve terminal membranes 
            enhance binding and uptake of GT1b-binding molecules
          </li>
          <li>
            <strong>Enhanced transport:</strong> Vaccine antigens with GT1b affinity are 
            transported more efficiently to the spinal cord
          </li>
          <li>
            <strong>Autoimmune trigger:</strong> Antigens released in lamina I trigger 
            autoimmune response against orexin neurons
          </li>
          <li>
            <strong>HLA contribution:</strong> DQB1*06:02 may still contribute by efficiently 
            presenting the cross-reactive epitopes — but it's secondary to the transport mechanism
          </li>
        </ol>

        <div class="info-box">
          <h4 class="font-bold text-blue-800 mb-2">Critical Research Questions</h4>
          <ul class="text-blue-700 text-sm mb-0 space-y-1">
            <li>• Are B3GALT4 expression levels elevated in DQB1*06:02 carriers?</li>
            <li>• Do narcolepsy patients have higher GT1b levels in peripheral nerves?</li>
            <li>• Are there specific B3GALT4 SNPs in linkage disequilibrium with DQB1*06:02?</li>
            <li>• Can B3GALT4 variants alone (without DQB1*06:02) confer susceptibility?</li>
          </ul>
        </div>

        <h2>The Missing Disease — Why GT1b Variants Go Undetected</h2>
        <p>
          A striking observation: while there are well-characterized storage diseases for most gangliosides, 
          <strong>there is no known disease caused by primary accumulation of GD1b or GT1b</strong>.
        </p>
        
        <table class="w-full text-sm my-6">
          <thead>
            <tr class="border-b bg-slate-50">
              <th class="text-left py-2 px-2">Ganglioside</th>
              <th class="text-left py-2 px-2">Accumulation Disease</th>
              <th class="text-left py-2 px-2">Enzyme Defect</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b">
              <td class="py-2 px-2">GM1</td>
              <td class="py-2 px-2">GM1 gangliosidosis</td>
              <td class="py-2 px-2">β-Galactosidase (GLB1)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2 px-2">GM2</td>
              <td class="py-2 px-2">Tay-Sachs, Sandhoff disease</td>
              <td class="py-2 px-2">Hexosaminidase A/B</td>
            </tr>
            <tr class="border-b">
              <td class="py-2 px-2">GM3</td>
              <td class="py-2 px-2">GM3 synthase deficiency</td>
              <td class="py-2 px-2">ST3GAL5</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2 px-2 font-bold">GD1b</td>
              <td class="py-2 px-2 text-slate-400 italic">None known</td>
              <td class="py-2 px-2">—</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2 px-2 font-bold">GT1b</td>
              <td class="py-2 px-2 text-slate-400 italic">None known</td>
              <td class="py-2 px-2">—</td>
            </tr>
          </tbody>
        </table>

        <div class="key-concept">
          <div class="key-concept-title">Why No GT1b Storage Disease?</div>
          <p>
            The answer lies in the <strong>shedding mechanism</strong>. B-series gangliosides (GD1b, GT1b, GQ1b) 
            are exported from neurons via <strong>extracellular vesicles (EVs/exosomes)</strong>. This 
            ceramide-dependent budding process acts as a "bypass" of normal lysosomal degradation:
          </p>
          <ul class="mt-2 mb-0 text-sm">
            <li>A-series (GM1, GM2): Low shedding → lysosomal accumulation → storage diseases</li>
            <li>B-series (GT1b, GQ1b): High shedding → extracellular export → <strong>no storage disease</strong></li>
          </ul>
          <p class="mt-2 mb-0 text-sm">
            However, this shedding <em>increases immune exposure</em> — glycan epitopes on shed EVs are 
            accessible to antibodies, explaining autoimmune syndromes like Miller Fisher (anti-GQ1b).
          </p>
        </div>

        <h3>Implications for the Hypothesis</h3>
        <p>
          This "invisible phenotype" has profound implications:
        </p>
        <ol>
          <li>
            <strong>No clinical flag:</strong> Individuals with B3GALT4 variants that increase GT1b 
            production would have no apparent disease — the excess GT1b is simply released extracellularly.
          </li>
          <li>
            <strong>Hidden susceptibility:</strong> The only "symptom" would be increased vulnerability 
            to GT1b-mediated pathogen transport — which would only manifest if exposed to the right trigger.
          </li>
          <li>
            <strong>The HLA paradox explained:</strong> This explains why HLA-DQB1*06:02 carriers have 
            no other phenotype besides narcolepsy susceptibility — the linked B3GALT4 variant affects 
            only extracellular GT1b release, not intracellular storage.
          </li>
          <li>
            <strong>Population frequency:</strong> Because there's no selective pressure against GT1b 
            accumulation variants, they may be relatively common in the population.
          </li>
        </ol>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">The Tetanus Toxin Parallel</h4>
          <p class="text-amber-700 text-sm mb-0">
            Unpublished research showed that tetanus toxin (GT1b-binding) is released extraneuronally 
            in the spinal cord, while cholera toxin (GM1-binding) remains confined to nerve terminals. 
            This differential behavior suggests GT1b has a unique "export" function that other 
            gangliosides lack — explaining both why GT1b doesn't cause storage disease AND why 
            GT1b-binding antigens can trigger autoimmune responses in the CNS.
          </p>
        </div>

      </div>
    </div>
  </section>
</BaseLayout>
